http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Immunocore presents new biomarker analysis for KIMMTRAK (tebentafusp-tebn) in metastatic uveal melanoma at the SITC 2022 Annual Meeting
-
Immunocore to present at the Jefferies London Healthcare Conference
-
Immunocore to present at the Jefferies London Healthcare Conference
-
Immunocore Reports Third Quarter 2022 Financial Results and Provides Business Update
-
Immunocore Reports Third Quarter 2022 Financial Results and Provides Business Update
-
Immunocore presents promising initial Phase 1 data for first off-the-shelf TCR therapy targeting PRAME at the ESMO 2022 Congress
-
Immunocore presents promising initial Phase 1 data for first off-the-shelf TCR therapy targeting PRAME at the ESMO 2022 Congress
-
Immunocore Reports Second Quarter 2022 Financial Results and Provides Business Update
-
Immunocore Reports Second Quarter 2022 Financial Results and Provides Business Update
-
Immunocore to Report Second Quarter 2022 Earnings and Host Call on August 10, 2022
-
Immunocore to Report Second Quarter 2022 Earnings and Host Call on August 10, 2022
-
Immunocore announces upcoming oral presentation of initial Phase 1 data of ImmTAC® candidate IMC-F106C targeting PRAME at European Society for Medical Oncology (ESMO) Congress 2022
-
Immunocore announces upcoming oral presentation of initial Phase 1 data of ImmTAC® candidate IMC-F106C targeting PRAME at European Society for Medical Oncology (ESMO) Congress 2022
-
Immunocore (IMCR) Announces 3.73M Share Private Placement at $37.50/sh
-
Immunocore Announces $140 Million Private Placement Financing
-
Immunocore Announces $140 Million Private Placement Financing
-
Immunocore announces dosing of first patient with ImmTAV® bispecific for HIV
-
Immunocore announces dosing of first patient with ImmTAV® bispecific for HIV
-
Immunocore (IMCR) Presents Initial Phase 1 Data of ImmTAV
-
Immunocore announces the presentation of initial data from the Phase 1 ImmTAV® trial for chronic Hepatitis B at the EASL International Liver Congress™
-
Immunocore announces the presentation of initial data from the Phase 1 ImmTAV® trial for chronic Hepatitis B at the EASL International Liver Congress™
-
LAVA Therapeutics Announces Two Appointments to its Board of Directors
-
Immunocore (IMCR) Appoints Siddharth (Sid) Kaul to its Board
-
Immunocore Appoints Siddharth Kaul to its Board of Directors
-
Immunocore Appoints Siddharth Kaul to its Board of Directors
-
Immunocore (IMCR) Announces UK MHRA, Australian TGA and Health Canada approve KIMMTRAK for the treatment of unresectable or metastatic uveal melanoma
-
The UK Medicines and Healthcare products Regulatory Agency (MHRA), Australian Therapeutic Goods Administration (TGA) and Health Canada approve KIMMTRAK® (tebentafusp) for the treatment of unresectabl
-
The UK Medicines and Healthcare products Regulatory Agency (MHRA), Australian Therapeutic Goods Administration (TGA) and Health Canada approve KIMMTRAK® (tebentafusp) for the treatment of unresectabl
-
Immunocore (IMCR) Presents Net KIMMTRAK Data
-
Immunocore presents new data on KIMMTRAK (tebentafusp-tebn) in metastatic cutaneous (mCM) and uveal melanoma (mUM) at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
-
Immunocore presents new data on KIMMTRAK (tebentafusp-tebn) in metastatic cutaneous (mCM) and uveal melanoma (mUM) at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
-
Immunocore (IMCR) Enters Clinical Trial Collaboration with Sanofi (SNY) For SAR444245
-
Immunocore announces clinical trial collaboration with Sanofi to evaluate Sanofi’s product candidate SAR444245, non-alpha IL-2, in combination with KIMMTRAK® in patients with metastatic cutaneous m
-
Immunocore announces clinical trial collaboration with Sanofi to evaluate Sanofi’s product candidate SAR444245, non-alpha IL-2, in combination with KIMMTRAK® in patients with metastatic cutaneous m
-
Immunocore to present at upcoming investor conferences
-
Immunocore to present at upcoming investor conferences
-
Immunocore announces upcoming presentations at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
-
Immunocore announces upcoming presentations at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
-
Immunocore Reports First Quarter 2022 Financial Results and Provides Business Update
-
Immunocore Reports First Quarter 2022 Financial Results and Provides Business Update
-
SOPHiA GENETICS Announces Nomination of Jean-Michel Cosséry to Board of Directors
-
Immunocore to present at the 21st Annual Needham Healthcare Conference
-
Immunocore to present at the 21st Annual Needham Healthcare Conference
-
Immunocore (IMCR) Announces EU Approval of KIMMTRAK
-
European Commission Approves KIMMTRAK® (tebentafusp) for the treatment of unresectable or metastatic uveal melanoma
-
European Commission Approves KIMMTRAK® (tebentafusp) for the treatment of unresectable or metastatic uveal melanoma
-
Immunocore to present at Oppenheimer’s 32nd Annual Healthcare Conference
-
Immunocore to present at Oppenheimer’s 32nd Annual Healthcare Conference
-
Immunocore Reports Full Year 2021 Financial Results and Provides Business Update
-
Immunocore Reports Full Year 2021 Financial Results and Provides Business Update
